EARTHRISE MEDICAL LIMITED
Opportunity 70/100 (strong), bankability 65/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Biggest value-creation lever: Broaden director team. Sole director creates succession risk and reduces buyer comfort. Appoint a second director or strong #2. Most likely exit: strategic trade sale (65/100).
Data confidence
Overall: medium (69/100)Adequate coverage. AI outputs are reliable for the sections scored high; verify the rest in diligence.
Solid opportunity signal. Worth a dedicated memo and management meeting.
Signals from accounts
Derived from iXBRL accounts · FRS 105 (micro)Key financials
1 year extracted from filed iXBRL accountsFinancials
Extracted from Companies House accounts · FRS 105 (micro)| Metric | 2025-05-31 |
|---|---|
| Total assets | £34.6k |
| Current assets | £42.4k |
| Net assets | £34.6k |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
Corporate timeline (5 events)Click to expand
- 2025-08-29📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2024-10-15📄capital-allotment-sharescapital · SH01
- 2024-05-08🏢Company incorporatedAs EARTHRISE MEDICAL LIMITED
- 2024-05-08➕MERARD, Reena, Dr appointeddirector
- 2024-05-08📄incorporation-companyincorporation · NEWINC
Owner dependency
The business appears inseparable from the founder. Acquisition without a serious earn-out or meaningful transition period would likely destroy value.
- +Sole director: Only one active director — all governance concentrated on one person.
- +Young company: Only 2.0 years old — management layer unlikely to be developed.
Succession & seller-readiness
Some succession indicators present. Worth watching; approach if sector/strategy fits.
- primarySole active director: Only one director in control. No visible successor — buyers solve the succession problem.
Red flags
cleanShareholders & ownership
1 active beneficial owner · dominant holder ≥75%| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Dr Reena Merard Individual · British · DOB 03/1978 · age 48 | 75–100% | 75–100% | board control75-100% shares · 75-100% voting · board control | 08/05/2024 |
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
Similar companies
Active · Healthcare & medical · EH postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| EIDYN CARE LTD→ SC544001 · est 2016 · no financials extracted | — | — | — | — | 9y | — | — |
| ELM PHYSIO LTD→ SC820810 · est 2024 · no financials extracted | — | — | — | — | 1y | — | — |
| ENCHANTED FOREST NURSERY (INVERKIP) LTD→ SC412812 · est 2011 · no financials extracted | — | — | — | — | 14y | — | — |
| ENGAGE CLINICAL PSYCHOLOGY LTD→ SC666815 · est 2020 · no financials extracted | — | — | — | — | 5y | — | — |
| EPI INTERVENTIONS LTD→ SC489789 · est 2014 · no financials extracted | — | — | — | — | 11y | — | — |
| EPIC ASSIST CHARITY→ SC455459 · est 2013 · no financials extracted | — | — | — | — | 12y | — | — |
| EYE SIRJHUN LTD→ SC846282 · est 2025 · no financials extracted | — | — | — | — | — | — | — |
| EYECARE-PLUS LTD→ SC249898 · est 2003 · no financials extracted | — | — | — | — | 22y | — | — |
| FOLA LIMITED→ SC387667 · est 2010 · no financials extracted | — | — | — | — | 15y | — | — |
| FORTH MUSIC THERAPY SERVICE LTD→ SC536361 · est 2016 · no financials extracted | — | — | — | — | 9y | — | — |
| FTT HEALTHCARE LTD→ SC767666 · est 2023 · no financials extracted | — | — | — | — | 2y | — | — |
| G46CONSULTING LIMITED→ SC645745 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
8 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Registered office
Filing status
Officers (1 active · 0 resigned)
Click a director name to see their full track record across all companies.